BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 8671786)

  • 1. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
    Sepandj F; Jindal K; West M; Hirsch D
    Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintaining iron balance with total-dose infusion of intravenous iron dextran.
    Case G
    ANNA J; 1998 Feb; 25(1):65-8. PubMed ID: 9543911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of parenteral iron regimens in hemodialysis patients.
    Besarab A; Kaiser JW; Frinak S
    Am J Kidney Dis; 1999 Jul; 34(1):21-8. PubMed ID: 10401011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective utilization of erythropoietin with intravenous iron therapy.
    Bhandari S; Brownjohn A; Turney J
    J Clin Pharm Ther; 1998 Feb; 23(1):73-8. PubMed ID: 9756115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
    Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
    Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
    Warady BA; Zobrist RH; Wu J; Finan E;
    Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis--the IDIRA Study.
    Rath T; Florschütz K; Kalb K; Rothenpieler U; Schletter J; Seeger W; Zinn S
    Nephron Clin Pract; 2010; 114(1):c81-8. PubMed ID: 19887827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
    DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
    Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
    Dahdah K; Patrie JT; Bolton WK
    Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety aspects of parenteral iron in patients with end-stage renal disease.
    Sunder-Plassmann G; Hörl WH
    Drug Saf; 1997 Oct; 17(4):241-50. PubMed ID: 9352960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
    Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
    Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment.
    Senger JM; Weiss RJ
    ANNA J; 1996 Jun; 23(3):319-23; discussion 324-5. PubMed ID: 8716991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.